Merck (MRK) Tops Q1 EPS by 11c; Bumps Non-GAAP FY15 Outlook

Merck (NYSE: MRK) reported Q1 EPS of $0.85, $0.11 better than the analyst estimate of $0.74. Revenue for the quarter came in at $9.4 billion versus the consensus estimate of $9.04 billion.

Merck narrowed and raises FY2015 Non-GAAP EPS to $3.35-$3.48, versus the consensus of $3.37. Lowers 2015 Full-Year GAAP EPS Target to $1.58 to $1.85

“Our strong performance this quarter demonstrates that our scientific and business strategies, together with our focused investments, are paying off.”

“We remain focused on bringing forward the best scientific and medical innovations.”

“By capitalizing on the exciting scientific and clinical opportunities that lie ahead, Merck is poised to play a major role in transforming health care for patients, as well as payers and shareholders.”

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
• Kite Realty sells City Center in White Plains for $50 million